Demographic representation in pivotal clinical trials for lymphoma therapies approved by the FDA between 2011 and 2021
| Demographic characteristics . | Overall (n = 4849) . | cHL (n = 1957) . | NHL (n = 2892) . |
|---|---|---|---|
| Age (mean) | 57.3 | 38.8 | 60.9 |
| Race (n, %)∗ | |||
| AI-AN | 11 (0.2) | 2 (0.1) | 9 (0.3) |
| ‡Asian-PI | 304 (6.3) | 129 (6.6) | 175 (6.1) |
| Black | 152 (3.1) | 71 (3.6) | 81 (2.8) |
| White | 4032 (83.2) | 1679 (85.8) | 2353 (81.4) |
| Other† | 36 (0.7) | 35 (1.8) | 1 (0.03) |
| Sex (n, %) | |||
| Males | 2884 (59.5) | 1122 (57.3) | 1762 (60.9) |
| Females | 1965 (40.5) | 835 (42.7) | 1130 (39.1) |
| § Ethnicity (n, %) | n = 3605 | n = 1626 | n = 1979 |
| Hispanic | 215 (6) | 109 (6.7) | 106 (5.4) |
| Non-Hispanic | 3044 (84.4) | 1337 (82.2) | 1707 (86.3) |
| U/NR/M | 346 (9.6) | 180 (11.1) | 166 (8.4) |
| Demographic characteristics . | Overall (n = 4849) . | cHL (n = 1957) . | NHL (n = 2892) . |
|---|---|---|---|
| Age (mean) | 57.3 | 38.8 | 60.9 |
| Race (n, %)∗ | |||
| AI-AN | 11 (0.2) | 2 (0.1) | 9 (0.3) |
| ‡Asian-PI | 304 (6.3) | 129 (6.6) | 175 (6.1) |
| Black | 152 (3.1) | 71 (3.6) | 81 (2.8) |
| White | 4032 (83.2) | 1679 (85.8) | 2353 (81.4) |
| Other† | 36 (0.7) | 35 (1.8) | 1 (0.03) |
| Sex (n, %) | |||
| Males | 2884 (59.5) | 1122 (57.3) | 1762 (60.9) |
| Females | 1965 (40.5) | 835 (42.7) | 1130 (39.1) |
| § Ethnicity (n, %) | n = 3605 | n = 1626 | n = 1979 |
| Hispanic | 215 (6) | 109 (6.7) | 106 (5.4) |
| Non-Hispanic | 3044 (84.4) | 1337 (82.2) | 1707 (86.3) |
| U/NR/M | 346 (9.6) | 180 (11.1) | 166 (8.4) |
AI-AN, American Indian-Alaska Native; M, missing; NR, not reported; PI, Pacific Islander; U, unknown.
The unknown or missing values were included in the denominator but not reported.
Includes “other” and “more than 1 race.”
The Asian-PI groups were combined.
Ethnicity results are based on data from 12 of 18 trials.